NEW YORK, Nov. 14 (GenomeWeb News) - Large Scale Biology said today it would conclude a toxoproteomic contract with the National Institute of Environmental Health Sciences-which was slated to continue for over three more years-and would "re-evaluate" its proteomic contract research business.
The company announced the contract with NIEHS in July 2002, which was a five-year, $12.25 million contract for analysis of samples for the National Center for Toxicogenomics.
The company said that the discontinuance of its contract was not due to any failure to deliver under research protocols or timetables, but "for the stated convenience of the government."
The company also indicated it would de-emphasize other contract proteomics work.
"As announced in April 2003, a re-evaluation of our 2Dimensional gel fee-for-service proteomic research business with the potential for attendant cost reduction is entirely consistent with our previously articulated strategic shift from platform technologies and contract proteomic research in favor of developing and commercializing vaccines and protein-based pharmaceutical products" Kevin Ryan, LSBC president, said in a statement.